Ironwood Pharmaceuticals Inc [IRWD] stock prices are up 7.49% to $4.59 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IRWD shares have gain 43.44% over the last week, with a monthly amount glided 23.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock has seen the most recent analyst activity on January 05, 2026, when Citizens JMP upgraded its rating to a Mkt Outperform but kept the price target unchanged to $8 for it. Previously, Wells Fargo downgraded its rating to Equal Weight on April 15, 2025. On April 15, 2025, downgrade downgraded it’s rating to Hold. Citizens JMP downgraded its rating to a Mkt Perform. Leerink Partners initiated its recommendation with a Market Perform and recommended $5 as its price target on September 09, 2024. CapitalOne downgraded its rating to Equal Weight for this stock on August 08, 2024, and downed its price target to $4. In a note dated January 17, 2024, Craig Hallum initiated an Buy rating and provided a target price of $21 on this stock.
The stock price of Ironwood Pharmaceuticals Inc [IRWD] has been fluctuating between $0.53 and $5.78 over the past year. Currently, Wall Street analysts expect the stock to reach $5.35 within the next 12 months. Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] shares were valued at $4.59 at the most recent close of the market. An investor can expect a potential return of 16.56% based on the average IRWD price forecast.
Analyzing the IRWD fundamentals
The Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] reported sales of 338.99M for trailing twelve months, representing a surge of 33.26%. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at 0.36%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.21, Equity is -0.34 and Total Capital is 0.8. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.78.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.39 points at the first support level, and at 4.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.91, and for the 2nd resistance point, it is at 5.22.
Ratios To Look Out For
It’s worth pointing out that Ironwood Pharmaceuticals Inc [NASDAQ:IRWD]’s Current Ratio is 1.13. As well, the Quick Ratio is 1.13, while the Cash Ratio is 0.58. Considering the valuation of this stock, the price to sales ratio is 2.20 and price to earnings (TTM) ratio is 29.73.
Transactions by insiders
Recent insider trading involved RONALD SILVER, Officer, that happened on Jan 05 ’26 when 35416.0 shares were purchased. Chief Commercial Officer, Gaskins Tammi L completed a deal on Nov 17 ’25 to sell 6016.0 shares. Meanwhile, Officer Gaskins Tammi L bought 6324.0 shares on Nov 17 ’25.
